Publicado 29/11/2016 1:02:42CET
Session Title: Treatment: New Drugs and Treatment Strategies
Session Date: 10/12/16
Session Time: 7.30 - 9.00
Location: Hall 1
Notes to Editors
About Metastatic Breast Cancer
More than 300,000 women are diagnosed with breast cancer in Europe every year and about one third subsequently develop metastatic disease. At this advanced stage, the cancer spreads beyond the breast to other parts of the body.
About Halaven(R) (eribulin)
Eribulin is the first in the halichondrin class of microtubule dynamics inhibitors with a novel mechanism of action. Structurally eribulin is a simplified and synthetically produced version of halichondrin B, a natural product isolated from the marine sponge Halichondria okadai. Eribulin is believed to work by inhibiting the growth phase of microtubule dynamics that prevents cell division.
The European Commission approved in May 2016 a variation to the terms of the Marketing Authorisation of eribulin for the treatment of adult patients with unresectable liposarcomas who have received prior anthracycline containing therapy (unless unsuitable) for advanced or metastatic disease.
Eisai in Oncology
Eisai is committed to the development and delivery of highly beneficial new treatments for people with cancer. The development of therapeutic options in oncology is a major strategic area for Eisai in Europe, the Middle East, Africa, Russia and Oceania (EMEA). In the European Union, Eisai currently has three marketed treatments across four indications:
- Lenvima(R) (lenvatinib) is indicated in the European Union for the treatment of
adult patients with progressive locally advanced or metastatic, differentiated
(papillary, follicular, Hürthle cell) thyroid carcinoma (DTC) refractory to
radioactive iodine (RAI).
- Kisplyx(R) (lenvatinib) is indicated in the European Union in combination with
everolimus for the treatment of adult patients with advanced renal cell carcinoma (RCC)
following one prior vascular endothelial growth factor (VEGF)-targeted therapy.
- Halaven(R) (eribulin) is indicated for the treatment of adult patients with locally
advanced or metastatic breast cancer who have received at least one chemotherapeutic
regimen for advanced disease. Prior therapy should have included an anthracycline and
a taxane in either the adjuvant or metastatic setting, unless patients were not
suitable for these treatments. Halaven(R) (eribulin) is also indicated for the
treatment of adult patients with unresectable liposarcomas who have received prior
anthracycline containing therapy (unless unsuitable) for advanced or metastatic
About Eisai Co., Ltd.
Eisai Co., Ltd. is a leading global research and development-based pharmaceutical company headquartered in Japan. We define our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care (hhc) philosophy. With over 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realise our hhc philosophy by delivering innovative products in multiple therapeutic areas with high unmet medical needs, including Oncology and Neurology.
As a global pharmaceutical company, our mission extends to patients around the world through our investment and participation in partnership-based initiatives to improve access to medicines in developing and emerging countries.
For more information about Eisai Co., Ltd., please visit http://www.eisai.com.
1. EMA, Halaven. Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002084/smops/Positive/human_smop_000955.jsp&mid=WC0b01ac058001d127 . Accessed November 2016
2. World Health Organisation. Atlas of Health in Europe. 2003. World Health Organization, Regional Office of Europe, Copenhagen, Denmark.
November 2016 Eribulin-EU0208
CONTACT: Media Enquiries: Eisai, Cressida Robson / Chloe Fox, +44 7908 314155/+44 7508 355 171, Cressida_Robson@eisai.net, Chloe_Fox@eisai.net, TonicLife Communications, Alex Davies / Callum Haire, +44 7716 324 722 / +447867 429 637, Alex.Davies@toniclc.com, Callum.Haire@toniclc.com